Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Achaogen Inc    AKAO

ACHAOGEN INC (AKAO)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/13/2017 11/14/2017 11/15/2017 11/16/2017 11/17/2017 Date
13.01(c) 11.92(c) 11.69(c) 11.95(c) 11.83(c) Last
545 559 1 235 134 878 341 711 306 737 892 Volume
-2.11% -8.38% -1.93% +2.22% -1.00% Change
More quotes
Financials ($)
Sales 2017 10,8 M
EBIT 2017 -119 M
Net income 2017 -121 M
Finance 2017 144 M
Yield 2017 -
Sales 2018 15,1 M
EBIT 2018 -143 M
Net income 2018 -138 M
Finance 2018 134 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 33,1x
EV / Sales2018 24,3x
Capitalization 502 M
More Financials
Company
Achaogen, Inc. is a late-stage biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments against multi-drug resistant gram-negative infections.It offers Plazomicin, which is a novel intravenous aminoglycoside antibiotic.The company was... 
More about the company
Surperformance© ratings of Achaogen Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACHAOGEN INC
11/14 ACHAOGEN : Reports Third Quarter 2017 Financial Results and Provides Corporate U..
11/09 ACHAOGEN : Studies from Achaogen, Inc. Have Provided New Information about Staph..
11/09 ACHAOGEN : to Present at the Stifel 2017 Healthcare Conference
11/08 ACHAOGEN : reports 3Q loss
11/08 ACHAOGEN : Management's Discussion and Analysis of Financial Condition and Resul..
11/08 ACHAOGEN INC : Results of Operations and Financial Condition, Financial Statemen..
11/08 Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate ..
11/08 ACHAOGEN INC : Achaogen, Inc. to Host Earnings Call
11/06 Achaogen to Present at the Stifel 2017 Healthcare Conference
11/01 ACHAOGEN : Announces New Employment Inducement Grants
More news
Sector news : Bio Therapeutic Drugs
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/10 Achaogen 2017 Q3 - Results - Earnings Call Slides
11/08 Achaogen's (AKAO) CEO Kenneth Hillan on Q3 2017 Results - Earnings Call Trans..
11/08 Achaogen misses by $0.13, misses on revenue
11/07 Notable earnings after Wednesday?s close
10/27 Can Achaogen Turn It Around After A Long Slide?
Chart ACHAOGEN INC
Duration : Period :
Achaogen Inc Technical Analysis Chart | AKAO | US0044491043 | 4-Traders
Technical analysis trends ACHAOGEN INC
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 24,1 $
Spread / Average Target 104%
EPS Revisions
Managers
NameTitle
Kenneth J. Hillan Chief Executive Officer & Director
Blake Wise President & Chief Operating Officer
Bryan E. Roberts Chairman
Tobin Schilke CFO & Principal Accounting Officer
Lee Swem Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ACHAOGEN INC-9.14%502
GILEAD SCIENCES0.28%94 562
REGENERON PHARMACEUTICALS5.23%42 405
VERTEX PHARMACEUTICALS101.79%37 414
GENMAB-3.41%11 744
EXELIXIS, INC.66.00%7 642